Attenuated replication and damaging effects of SARS‐CoV‐2 Omicron variants in an intestinal epithelial barrier model
Open Access
- 5 July 2024
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (7) , e29783
Abstract
Many COVID‐19 patients suffer from gastrointestinal symptoms and impaired intestinal barrier function is thought to play a key role in Long COVID. Despite its importance, the impact of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on intestinal epithelia is poorly understood. To address this, we established an intestinal barrier model integrating epithelial Caco‐2 cells, mucus‐secreting HT29 cells and Raji cells. This gut epithelial model allows efficient differentiation of Caco‐2 cells into microfold‐like cells, faithfully mimics intestinal barrier function, and is highly permissive to SARS‐CoV‐2 infection. Early strains of SARS‐CoV‐2 and the Delta variant replicated with high efficiency, severely disrupted barrier function, and depleted tight junction proteins, such as claudin‐1, occludin, and ZO‐1. In comparison, Omicron subvariants also depleted ZO‐1 from tight junctions but had fewer damaging effects on mucosal integrity and barrier function. Remdesivir, the fusion inhibitor EK1 and the transmembrane serine protease 2 inhibitor Camostat inhibited SARS‐CoV‐2 replication and thus epithelial barrier damage, while the Cathepsin inhibitor E64d was ineffective. Our results support that SARS‐CoV‐2 disrupts intestinal barrier function but further suggest that circulating Omicron variants are less damaging than earlier viral strains.Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patientsInfection, 2022
- SARS-CoV-2 infection causes intestinal cell damage: Role of interferon’s imbalanceCytokine, 2022
- Viral Transduction Enhancing Effect of EF‐C Peptide Nanofibrils Is Mediated by Cellular ProtrusionsAdvanced Functional Materials, 2021
- The characteristics of gastrointestinal symptoms in patients with severe COVID-19: a systematic review and meta-analysisJournal of Gastroenterology, 2021
- Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activityEBioMedicine, 2021
- Organ-specific manifestations of COVID-19 infectionClinical and Experimental Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Molecular insights into the mechanisms of M-cell differentiation and transcytosis in the mucosa-associated lymphoid tissuesAnatomical Science International, 2017
- Intestinal Goblet Cells and Mucins in Health and Disease: Recent Insights and ProgressCurrent Gastroenterology Reports, 2010
- Computer Visualization of Three-Dimensional Image Data Using IMODJournal of Structural Biology, 1996